weight loss, compounding and Food and Drug Administration

Ending of US weight-loss drug shortages prompts compounder complaints
Novo Nordisk’s semaglutide diabetes and weight loss drugs, Ozempic and Wegovy, are no longer officially in shortage in the US, according to the US Food and Drug Administration (FDA). That means that compounding pharmacies and outsourcing facilities that had been legitimately preparing their own versions of the drugs will no longer be permitted to do so.
Compound versions of some weight loss drugs to be restricted
Zepbound contains the same active ingredient, tirzepatide, as Mounjaro, which is also made by Lilly and is FDA-approved to treat Type 2 diabetes. Some doctors also prescribe Mounjaro "off-label" for weight loss, as is permissible by the FDA.
Weight-loss drug battle: Who are the latest players involved
The weight-loss drug market is evolving at a rapid speed, with leading pharma companies including Novo Nordisk and Eli Lilly diving into the opportunity to make anti-obesity products. This article looks into key players in the arena.
What is Metformin? All you need to know about the old diabetes drug some people are taking for weight loss
Hims & Hers' lower-priced injectable semaglutide promoted during the Super Bowl has led to some patients receiving the more affordable metformin inste
Who can get weight loss drugs on the NHS in Scotland?
The medicines watchdog has agreed the drugs are safe and cost-effective for NHS use. Last year, semaglutide was approved for treating obesity under the brand name Wegovy. It has also been licensed under the brand name Ozempic for treating diabetes in some circumstances,
Compound versions of weight loss drugs will no longer be available, FDA rules
Compounded versions of popular drugs used for weight loss including Wegovy and Zepbound will soon no longer be available after a decision by the U.S. Food and Drug Administration. The agency has ordered compounding pharmacies to stop making compound versions of GLP-1 drugs now that the drugs are no longer in short supply.
Medications For Weight Loss
Dr. Alexandro Zarruk, MD, MSc., FACP, FRCPC, Internal Medicine, talks about medications that can help patients lose weight.
Federal judge stops compounded copies of Eli Lilly weight loss, diabetes drugs
A federal judge has effectively ended the ability of compounding pharmacies to make their own copies of Eli Lilly’s weight ...
Ozempic vs Metformin For Weight Loss: Which Is Best for Me?
The increasing popularity of weight loss drugs like Wegovy, Ozempic, Mounjaro and metformin may have you wondering how all ...
Novo Nordisk Drops Price of Weight-Loss Drug Wegovy for Some Patients Paying Out of Pocket
Novo Nordisk is lowering the price of its weight-loss drug Wegovy to $499 per month for some patients paying out of pocket.
Novo Nordisk shares fall on weight-loss drug trial
Novo Nordisk released the results from its late-stage trial of CagriSema on Monday. It showed that patients on the highest dose of the drug lost 15.7% of their weight.
C&EN8d
Good old pills vie for weight-loss market
The FDA initially approved the peptides to treat diabetes ... danuglipron in Phase 2 trials as an antidiabetic and weight-loss drug. The foundational work that jump-started the development ...
Novo Nordisk Joins Legal Battle Over Weight Loss Drug Shortage
Novo Nordisk A/S can intervene in a lawsuit between the FDA and drug compounders over whether its blockbuster drugs Wegovy ...
Medscape6d
As Trump Administration Probes Long-Approved Medications, Could FDA Revoke Approvals?
A new federal commission will ‘investigate’ decades-old mental health as well as weight loss drugs, prompting concerns from ...
JD Supra13d
FDA Announces End to Semaglutide Shortage, Impacting Compounders and Telehealth Providers Offering Injectable GLP-1 Drugs
Last week, the US Food and Drug Administration (FDA) announced the end of a years-long shortage of semaglutide injection products — a ...